These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

59 related items for PubMed ID: 1428409

  • 1. Bispecific antibody therapy of two murine B-cell lymphomas.
    Demanet C, Brissinck J, Moser M, Leo O, Thielemans K.
    Int J Cancer Suppl; 1992; 7():67-8. PubMed ID: 1428409
    [Abstract] [Full Text] [Related]

  • 2. Immunotherapy with bispecific antibodies.
    Thielemans KM.
    Verh K Acad Geneeskd Belg; 1995; 57(3):229-47; discussion 247-8. PubMed ID: 7483816
    [Abstract] [Full Text] [Related]

  • 3. Treatment of murine B cell lymphoma with bispecific monoclonal antibodies (anti-idiotype x anti-CD3).
    Demanet C, Brissinck J, Van Mechelen M, Leo O, Thielemans K.
    J Immunol; 1991 Aug 01; 147(3):1091-7. PubMed ID: 1830596
    [Abstract] [Full Text] [Related]

  • 4. Role of T-cell subsets in the bispecific antibody (anti-idiotype x anti-CD3) treatment of the BCL1 lymphoma.
    Demanet C, Brissinck J, Leo O, Moser M, Thielemans K.
    Cancer Res; 1994 Jun 01; 54(11):2973-8. PubMed ID: 8187084
    [Abstract] [Full Text] [Related]

  • 5. Bispecific anti-idiotype/anti-CD3 antibody therapy of murine B cell lymphoma.
    Weiner GJ, Hillstrom JR.
    J Immunol; 1991 Dec 01; 147(11):4035-44. PubMed ID: 1834746
    [Abstract] [Full Text] [Related]

  • 6. Treatment of mice bearing BCL1 lymphoma with bispecific antibodies.
    Brissinck J, Demanet C, Moser M, Leo O, Thielemans K.
    J Immunol; 1991 Dec 01; 147(11):4019-26. PubMed ID: 1940384
    [Abstract] [Full Text] [Related]

  • 7. Idiotype vaccination strategies against a murine B-cell lymphoma: dendritic cells loaded with idiotype and bispecific idiotype x anti-class II antibodies can protect against tumor growth.
    Bohlen H, Thielemanns K, Tesch H, Engert A, Wolf HJ, van Camp B, Urbain J, Diehl V.
    Cytokines Mol Ther; 1996 Dec 01; 2(4):231-8. PubMed ID: 9384709
    [Abstract] [Full Text] [Related]

  • 8. The role of T cell activation in anti-CD3 x antitumor bispecific antibody therapy.
    Weiner GJ, Kostelny SA, Hillstrom JR, Cole MS, Link BK, Wang SL, Tso JY.
    J Immunol; 1994 Mar 01; 152(5):2385-92. PubMed ID: 8133049
    [Abstract] [Full Text] [Related]

  • 9. Bispecific IgG and IL-2 therapy of a syngeneic B-cell lymphoma in immunocompetent mice.
    Weiner GJ.
    Int J Cancer Suppl; 1992 Mar 01; 7():63-6. PubMed ID: 1428408
    [Abstract] [Full Text] [Related]

  • 10. Visualization of effective tumor targeting by CD8+ natural killer T cells redirected with bispecific antibody F(ab')(2)HER2xCD3.
    Scheffold C, Kornacker M, Scheffold YC, Contag CH, Negrin RS.
    Cancer Res; 2002 Oct 15; 62(20):5785-91. PubMed ID: 12384539
    [Abstract] [Full Text] [Related]

  • 11. Prevention of Epstein-Barr virus-induced human B-cell lymphoma in severe combined immunodeficient mice treated with CD3xCD19 bispecific antibodies, CD28 monospecific antibodies, and autologous T cells.
    Bohlen H, Manzke O, Titzer S, Lorenzen J, Kube D, Engert A, Abken H, Wolf J, Diehl V, Tesch H.
    Cancer Res; 1997 May 01; 57(9):1704-9. PubMed ID: 9135012
    [Abstract] [Full Text] [Related]

  • 12. Cytolysis of leukemic B-cells by T-cells activated via two bispecific antibodies.
    Bohlen H, Manzke O, Patel B, Moldenhauer G, Dörken B, von Fliedner V, Diehl V, Tesch H.
    Cancer Res; 1993 Sep 15; 53(18):4310-4. PubMed ID: 7689932
    [Abstract] [Full Text] [Related]

  • 13. Construction and in vivo evaluation of an anti-PSA x anti-CD3 bispecific antibody for the immunotherapy of prostate cancer.
    Katzenwadel A, Schleer H, Gierschner D, Wetterauer U, Elsässer-Beile U.
    Anticancer Res; 2000 Sep 15; 20(3A):1551-5. PubMed ID: 10928069
    [Abstract] [Full Text] [Related]

  • 14. Targeting gastrin-releasing peptide receptors on small cell lung cancer cells with a bispecific molecule that activates polyclonal T lymphocytes.
    Zhou J, Chen J, Zhong R, Mokotoff M, Shultz LD, Ball ED.
    Clin Cancer Res; 2006 Apr 01; 12(7 Pt 1):2224-31. PubMed ID: 16609038
    [Abstract] [Full Text] [Related]

  • 15. Redirected T-cell cytotoxicity to epithelial cell adhesion molecule-overexpressing adenocarcinomas by a novel recombinant antibody, E3Bi, in vitro and in an animal model.
    Ren-Heidenreich L, Davol PA, Kouttab NM, Elfenbein GJ, Lum LG.
    Cancer; 2004 Mar 01; 100(5):1095-103. PubMed ID: 14983507
    [Abstract] [Full Text] [Related]

  • 16. In vivo retargeting of T cell effector function by recombinant bispecific single chain Fv (anti-CD3 x anti-idiotype) induces long-term survival in the murine BCL1 lymphoma model.
    De Jonge J, Heirman C, de Veerman M, Van Meirvenne S, Moser M, Leo O, Thielemans K.
    J Immunol; 1998 Aug 01; 161(3):1454-61. PubMed ID: 9686611
    [Abstract] [Full Text] [Related]

  • 17. Anti-CD3 x anti-tumor F(ab')2 bifunctional antibody activates and retargets tumor-infiltrating lymphocytes.
    Chapoval AI, Nelson H, Thibault C.
    J Immunol; 1995 Aug 01; 155(3):1296-303. PubMed ID: 7636196
    [Abstract] [Full Text] [Related]

  • 18. Activated T-cell-mediated immunotherapy with a chimeric receptor against CD38 in B-cell non-Hodgkin lymphoma.
    Mihara K, Yanagihara K, Takigahira M, Imai C, Kitanaka A, Takihara Y, Kimura A.
    J Immunother; 2009 Sep 01; 32(7):737-43. PubMed ID: 19561535
    [Abstract] [Full Text] [Related]

  • 19. CD8+ T-cell-dependent immunity following xenogeneic DNA immunization against CD20 in a tumor challenge model of B-cell lymphoma.
    Palomba ML, Roberts WK, Dao T, Manukian G, Guevara-Patiño JA, Wolchok JD, Scheinberg DA, Houghton AN.
    Clin Cancer Res; 2005 Jan 01; 11(1):370-9. PubMed ID: 15671568
    [Abstract] [Full Text] [Related]

  • 20. Murine tumor cell lysis by antibody-dependent macrophage-mediated cytotoxicity using syngeneic monoclonal antibodies.
    Kawase I, Komuta K, Ogura T, Fujiwara H, Hamaoka T, Kishimoto S.
    Cancer Res; 1985 Apr 01; 45(4):1663-8. PubMed ID: 3978634
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 3.